A novel HLA-C*17 variant, HLA-C*17:01:01:29, identified in a healthy individual from Greece
- PMID: 38526343
- DOI: 10.1111/tan.15447
A novel HLA-C*17 variant, HLA-C*17:01:01:29, identified in a healthy individual from Greece
Abstract
HLA-C*17:01:01:29 differs from the HLA-C*17:01:01:05 allele by one nucleotide substitution in the 3'UTR.
Keywords: HLA‐C*17:01:01:29 novel allele; Illumina; next‐generation sequencing.
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Wang Y, Jasinski‐Bergner S, Wickenhauser C, Seliger B. Cancer immunology: immune escape of tumors‐expression and regulation of HLA class I molecules and its role in immunotherapies. Adv Anat Pathol. 2023;30:148‐159. doi:10.1097/PAP.0000000000000389
-
- Kouniaki DI, Fotopoulos KV, Tarassi K, Tsirogianni A. Utilizing massively parallel sequencing (MPS) of human leukocyte antigen (HLA) gene polymorphism to assess relatedness in deficiency parentage testing. Genes (Basel). 2024;15:150. doi:10.3390/genes15020150
-
- Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75:291‐455. doi:10.1111/j.1399‐0039.2010.01466.x
-
- Barker DJ, Maccari G, Georgiou X, et al. The IPD‐IMGT/HLA database. Nucleic Acids Res. 2023;51:D1053‐D1060. doi:10.1093/nar/gkac1011
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
